Stock Ticker

  • Loading stock data...

Gilead Sciences, Inc. (NASDAQ:GILD) Reports Minor Benefits Of Remdesivir In COVID-19 Patients

Gilead Sciences, Inc. (NASDAQ:GILD) released an update about its developmental COVID-19 vaccine remdesivir, revealing that the treatment yielded modest improvements in patients. Coronavirus patients who were administered with remdesivir intravenously for five days demonstrated moderate improvements. However, the COVID-19 patients that were treated with the drug for 10-days did not yield significant improvements. Remdesivir was […]

Gilead Sciences, Inc (NASDAQ:GILD) Speaks Out On The Trial Of Its Remdesivir Drug

Gilead Sciences, Inc (NASDAQ:GILD) is pleased to report about the success it is witnessing with its vaccine Remdesivir. The scientists have been working on the product in the hope that it would turn out to be the vaccine that would possibly help in dealing with COVID-19. Gilead has given an update outlining that it is […]

Gilead Sciences’ (NASDAQ:GILD) Potential COVID-19 Treatment Can Not Undo Damage On The US Economy

Gilead Sciences (NASDAQ:GILD) has a promising COVID-19 cure called remdesivir which caused US equity markets to surge on Friday. However, the surge in the stock market on Friday isn’t something justifiable. Is the economy gearing for fake markets? For stock markets, it has been a gloomy past few weeks and the economy could receive a […]

Gilead Sciences Inc. (NASDAQ:GILD) Commences Two Phase 3 Clinical Trials of Remdesivir For COVID-19 Treatment

Gilead Sciences Inc. (NASDAQ:GILD) has announced that it is expanding clinical trials for its antiviral drug remdesivir as a potential treatment of COVID-19 in countries outside China. Gilead to expand clinical trials of remdsivir to other countries outside china The company now expects to begin two new remdesivir clinical trials in March across Asia and […]

Plandai Biotechnology Inc (OTCMKTS:PLPL) Extends Its Association With USN (EDXC, GILD)

Plandai Biotechnology Inc (OTCMKTS:PLPL) reported that Ultimate Sports Nutrition is designing a new product line targeting the New Zealand and Australian markets. This line of products will be formulated using company’s patented Phytofare® complex. As per the new contract, the USN can assess the applications of the Phytofare® with other contract manufacturers. The idea is […]

Plandai Biotechnology Inc (OTCMKTS:PLPL) And ENDEXX CORP (OTCMKTS:EDXC) Plunges, Gilead Sciences, Inc. (NASDAQ:GILD) Consolidates

On Friday’s trading session, Plandai Biotechnology Inc (OTCMKTS:PLPL) and ENDEXX CORP (OTCMKTS:EDXC) declined 10.56% and 6.54%, respectively to close the week in deep red. However, major biotech firm Gilead Sciences, Inc. (NASDAQ:GILD) managed to halt its decline and consolidated to close almost flat at $107.78. The buzz Plandai Biotechnology earlier disclosed that Ultimate Sports Nutrition […]

Johnson & Johnson (NYSE:JNJ) To Revive Its Non-Prescription Medicines Business

Johnson & Johnson (NYSE:JNJ) might successfully reopen its Non-prescription medicines business that was shut down initially due to recalls. Over the past few years, the business suffered due to numerous recalls for some of its products. The company called back more than 135 million medicine bottles after tiny chunks of metal was discovered in Tylenol, […]

Gilead Sciences, Inc. (NASDAQ:GILD) Acquires Epiterapeutics For $65 million

Gilead Sciences, Inc. (NASDAQ:GILD) has acquired the private company EpiTherapeuticsApS in a deal worth $65 million. The deal gives Gilead a foothold in the field of epigenetics. The Denmark-based EpiTherapeutics develops cancer therapy and focuses on enzymes involved in the regulation of transcription in cancer. Gilead already has two drugs for hepatitis C, Harvoni and […]

Tobira Therapeutics Inc (NASDAQ:RGDO) raises $40 million through Merger with Regado

Tobira Therapeutics Inc (NASDAQ:RGDO) has executed a reverse merger with Regado Bioscience raising $40 million. The money is targeted at a pervasive liver disease. Tobira will get $27 million in a stock sale and $13 million in debt which has already been converted to common stock. On Tuesday, Tobira made a 9 for one reverse […]

Gilead Sciences, Inc. (NASDAQ:GILD) Gaffe Leads Drug Makers To Pledge More Openness On Price

Drug makers are worried about the market reaction over increasing drug prices especially after what happened to Gilead Sciences, Inc. (NASDAQ:GILD) over the Solvadi cure for Hepatitis C. Drug companies such as Sanofi SA (ADR) (NYSE:SNY) and Biogen Inc (NASDAQ:BIIB) expressed their concerns following the undesirable response that Gilead received in 2013. The company had […]

Merck & Co., Inc. (NYSE:MRK) and Gilead Sciences, Inc. (NASDAQ:GILD) Prepare for Battle over Next generation Hepatitis C drug

Merck & Co., Inc. (NYSE:MRK) and Gilead Sciences, Inc. (NASDAQ:GILD) both released new data on their next generation hepatitis C combo. The competition for market share is at an all-time high. Gilead Sciences, Inc. (NASDAQ:GILD) was the first one to release mid-stage data for its triple hepatitis C drug. The drug was combined with the […]

Gilead Sciences, Inc. (NASDAQ:GILD) Wins Street’s Hearts With Competitive Hepatitis C Drug Pricing

Boston, MA 10/13/2014 (wallstreetpr) – Gilead Sciences, Inc. (NASDAQ:GILD) is expected to reflect the positivity of the last week in its share prices today as well. The pharma company achieved a major milestone two days back when it recieved the U.S. Food and Drug Administration (FDA)’s nod for its hepatitis C drug. The regulatory approval […]

Gilead Sciences, Inc. (NASDAQ:GILD) Gets Positive View On Its Marketing Aapplication For Its Harvoni From European Regulator

Boston, MA 09/29/2014 (wallstreetpr) – Biopharmaceutical company, Gilead Sciences, Inc. (NASDAQ:GILD), disclosed that the European medicines agency, Committee for Medicinal Products for Human Use or CHMP, has taken a favorable view on its Market Authorization Application or MAA for its investigational once-daily tablet, Harvoni. The drug is meant for treating the adults infected by chronic hepatitis […]

Gilead Sciences, Inc. (NASDAQ:GILD): Invest in all dips

Boston, MA 09/26/2014 (wallstreetpr) – Gilead Sciences, Inc. (NASDAQ:GILD) (Closed: 107.34, Down: 1.26%) had a down day again after two sessions of small rise. The last rise from the last week low of $99.23 has been punctuated by down days nearly every alternate day and hence doesn’t look powerful enough to be called an impulsive […]

Gilead Sciences, Inc. (NASDAQ:GILD) Collaborates With Indian Pharmas For Cheaper Hepatitis C Drug In Developing Nations

Boston, MA 09/16/2014 (wallstreetpr) – In order to sell hepatitis C pill- Sovaldi, in developing countries like South Africa, Vietnam and Honduras, Gilead Sciences, Inc. (NASDAQ:GILD) authorized various drug companies in India. The actual price of hepatitis C pill of the company is $1,000-a-day, which will now be sold at just a dime in the […]

Sign Up To Get Our Latest Stocks Alerts